RxDoctor Payments Data

Sheri Crummey

Family · Hurst, TXNPI 1417097643

Payments from drug & device makers

$7,855in general payments, 2019–2025

Across 427 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Boston Scientific$662
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$438
  • Collegium Pharmaceutical, Inc.$382
  • Si-bone, Inc.$238
  • MML US, Inc.$210
  • plus $859 from 18 others

What the payments were for

  • Travel & lodging$6228%
  • Food & beverage$7,21192%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,855 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$30,075
Medicare patients
86
Services billed
989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl81$69,110
Buprenorphine123$24,044
MovantikNaloxegol Oxalate50$20,302
Nurtec OdtRimegepant Sulfate12$18,580
Aimovig AutoinjectorErenumab-Aooe19$14,223
Lidocaine135$13,849
Emgality PenGalcanezumab-Gnlm16$10,464
ZtlidoLidocaine13$10,374
Gabapentin584$10,274
LinzessLinaclotide17$9,325
LyricaPregabalin11$9,058
Pregabalin292$6,102
Tizanidine Hcl325$4,653
Cyclobenzaprine Hcl377$4,038
Methocarbamol175$3,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$382$69,11081 claims
PfizerNurtec Odt, Lyrica$148$27,63823 claims
Hikma Pharmaceuticals USABuprenorphine$65$24,044123 claims
Redhill Biopharma Inc.Movantik$15$20,30250 claims
Scilex Pharmaceuticals Inc.Ztlido$127$10,37413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Hurst

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →